Kaplan-Meier survival curves for overall survival in 42 patients with non-M3 AML (A) and 25 patients with CN-AML (B) in the validation cohort. The median value of BM LGALS3 expression in the original cohort of 280 patients was used as the cutoff point to define lower- and higher-expression groups.